Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xolair
Pharma
FDA approves Sanofi, Regeneron’s Dupixent for hives disorder
Once rejected in the indication, Sanofi and Regeneron have scored an FDA approval for Dupixent to treat chronic spontaneous urticaria.
Kevin Dunleavy
Apr 18, 2025 11:47am
In food allergy trial, Roche's Xolair tops oral immunotherapy
Mar 3, 2025 11:00am
Novartis plots 139 layoffs in NJ, largely affecting field sales
Nov 26, 2024 4:30pm
Sanofi, Regeneron to seek FDA nod for Dupixent in hives disorder
Sep 11, 2024 1:00am
FDA approves Roche, Novartis' Xolair for common food allergies
Feb 16, 2024 2:28pm
Roche's Xolair moves closer to food allergy approval from FDA
Dec 19, 2023 1:01pm
